Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Marie Sebert, Elodie Lainey, PAscale Lepelley, Sylvain Thepot, Maximilien Tailler, Claude Gardin, MD, Guido Kroemer, MD, PhD, Simone Boehrer, Lionel Ades, Pierre Fenaux, MD, PhD

Blood (2011) 118 (21): 5028.

https://doi.org/10.1182/blood.V118.21.5028.5028

Published: 2011

Journal Articles

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Elodie Lainey, Marie Sebert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, MD, Guido Kroemer, MD, PhD, Pierre Fenaux, MD, PhD, Simone Boehrer, MD, PhD

Blood (2011) 118 (21): 2790.

https://doi.org/10.1182/blood.V118.21.2790.2790

Published: 2011

Journal Articles

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Blood (2011) 118 (21): 2564.

https://doi.org/10.1182/blood.V118.21.2564.2564

Published: 2011

Journal Articles

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

Elodie Lainey, Marie Sebert, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Guido Kroemer, Pierre Fenaux, MD, PhD, Simone Boehrer

Blood (2010) 116 (21): 974.

https://doi.org/10.1182/blood.V116.21.974.974

Published: 2010

Journal Articles

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Marie Sebert, Elodie Lainey, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Pierre Fenaux, MD, PhD, Guido Kroemer, Simone Boehrer

Blood (2010) 116 (21): 2163.

https://doi.org/10.1182/blood.V116.21.2163.2163

Published: 2010

NARROW

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Email alerts

ASH Publications

American Society of Hematology

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only